What the common lipid results mean
- LDL cholesterol: a major atherogenic cholesterol measure and an important treatment target.
- Triglycerides: often rise with diabetes, insulin resistance, obesity, alcohol, diet, medicines or genetic factors; very high levels can raise pancreatitis risk.
- HDL cholesterol: part of risk interpretation, but trying to raise HDL with a medicine is not a substitute for lowering harmful lipoprotein exposure.
- Non-HDL cholesterol and ApoB: may better reflect the total burden of atherogenic particles in selected patients, especially when triglycerides are high.
- Lipoprotein(a): an inherited risk marker that current 2026 guidance recommends measuring at least once in adulthood where testing is available.
Who may benefit from a consultation?
- high LDL cholesterol or triglycerides on repeated testing;
- diabetes, chronic kidney disease, hypertension or fatty liver with lipid concerns;
- a personal history of heart attack, stroke, peripheral artery disease or coronary treatment;
- a strong family history of early cardiovascular disease or very high cholesterol;
- possible medicine side effects, statin intolerance or uncertainty about several treatment options;
- severe triglyceride elevation or concern about pancreatitis risk.
Treatment is matched to risk
Nutrition, physical activity, avoiding tobacco, blood-pressure control, diabetes care, sleep and weight management remain important. When medicine is indicated, statins are a foundation for many patients because of their outcome evidence. Other options may be appropriate when risk remains high, targets are not reached or adverse effects limit treatment. The exact plan depends on the clinical setting and local availability.
Current 2026 ACC/AHA guidance emphasizes earlier risk assessment, renewed LDL and non-HDL goals, and selective use of ApoB, lipoprotein(a) and coronary calcium scoring. These recommendations were developed primarily for U.S. practice and still require clinical judgement when applied in Pakistan.
Searching for the best cholesterol doctor in Lahore?
Look for a clinician who interprets the whole cardiovascular-risk picture, checks possible secondary causes, explains expected benefit and side effects, and follows the response. A single laboratory value or promotional title is not enough.
Primary guidance
- 2026 ACC/AHA multisociety guideline on the management of dyslipidaemia, published March 2026.
- American Heart Association: top clinical messages from the 2026 dyslipidaemia guideline, updated March 2026.
This page is general education. Do not start, stop or change cholesterol or triglyceride medicine without individualized medical advice.